THE PREVALENCE OF HEPATITIS C VIRUS INFECTION AND POTENTIAL RISK FACTORS AMONG MULTIPLY TRANSFUSED PATIENTS

Authors

  • Manal Khudder Abdul Razak Department of Medicine, Baghdad College of Medicine, University of Baghdad, Bab Al-Muadham Campus, Baghdad Iraq.

DOI:

https://doi.org/10.22159/ajpcr.2019.v12i1.29515

Keywords:

Hepatitis C virus, Multitransfusion, Prevalence

Abstract

Objective: Patients who frequently receive blood have high risk of hepatitis C virus (HCV) infection. This study aimed to evaluate the prevalence of HCV infection and potential risk factors among multiply transfused patients.

Methods: A cross-sectional retrospective study was conducted in the hemophilia unit in Medical City in Baghdad, between June 1, 2016, and January 1, 2017. After taking consents and approval of ethical comity, the medical records of 1158 patients with hemophilia A and B, von Willebrand disease (vWD), thrombasthenia, Factors VII, X, and XIII deficiencies, and hypofibrinogenemia were analyzed for the presence of HCV antibody using (enzyme-linked immunosorbent assay). Cases of hemophilia were classified into mild, moderate, and severe.

Results: The prevalence of HCV infection was 13.2%. Of total, 595 (51.4%) patients had hemophilia A and 99 (16.6%) were anti-HCV positive, while 225 (19.4%) had hemophilia B and 28 (12.4%) were antibody positive compared to 9 (7%) in vWD. Of those with hemophilia A, 515 (86.6%) had severe hemophilia, and 32 (32.32%) cases had acquired HCV infection after 1996 (after introduction of HCV screening in blood banks in Iraq). There was a statistically significant association with treatment by Factor VIII only.

Conclusion: The prevalence of HCV in patients with inherited bleeding disorder is 13.2%. In this study, it was found that multitransfusion is the only predictor for HCV infection in this group of patients.

 

Downloads

Download data is not yet available.

References

World Health Organization. Hepatitis C. WHO Fact Sheets No 164; 9 April 2014. Available from: http://www.searo.who.int/thailand/ factsheets/fs0018/en/. [Last accessed on 2017 Feb 26].

Ringelhan M, McKeating JA, Protzer U. Viral hepatitis and liver cancer. Philos Trans R Soc Lond B Biol Sci 2017;372:20160274.

Aruda V, High KA. Acute viral hepatitis. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, editors. Harrison’s Principles of Internal Medicine. 17th ed. New York: McGraw-Hill; 2012.

Nassiri TM, Lak M, Karimi K, Managhchi M, Samimi-Rad K, Abdollahi A. Seroprevalence of human immunodeficiency virus (HIV) and hepatitis C infection in hemophilic patients in Iran. Iran J Pathol 2008;3:119-24.

O’Leary JG, Davis GL. Hepatitis C. In: Feldman M, Friedman LS, Brandt LJ, editors. Sleisenger and Fordtran’s. Gastrointestinal and Liver Disease. 10th ed. Philadelphia, PA: Saunders Elsevier; 2010. p. 1313-35.

Desai NA, Kotak KP, Patel SS. Investigation of epidemiology and etiology of liver diseases and characterization of its association with various factors. Asian J Pharm Clin Res 2015;8:346-9.

Alavian SM, Tabatabaei SV, Keshvari M, Behnava B, Miri SM, Elizee PK, et al. Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: A single-centre study of 367 cases. Liver Int 2010;30:1173-80.

World Federation of Hemophilia. Severity of Hemophilia A. Hemophilia News Today; 2012.

Sharifi-Mood B, Eshghi P, Sanei-Moghaddam E, Hashemi M. Hepatitis B and C virus infections in patients with hemophilia in Zahedan, Southeast Iran. Saudi Med J 2007;28:1516-9.

Zahedi MJ, Darviesh MS. Assessment of prevalence of hepatitis B and C in hemophilic patients in Kerman in 1383. J Kerman Univ Med Sci 2008;3:131-5.

Yazdani MR, Kassaian N, Ataei B, Nokhodian Z, Adibi P. Hepatitis C virus infection in patients with hemophilia in Isfahan, Iran. Int J Prev Med 2012;3:S89-93.

Jang TY, Lin PC, Huang CI, Liao YM, Yeh ML, Zeng YS, et al. Seroprevalence and clinical characteristics of viral hepatitis in transfusion-dependent thalassemia and hemophilia patients. PLoS One 2017;12:e0178883.

Naghmi A, Tahira Z, Khalid H, Lubna N. Seroprevalence anti HCV antibodies, HCV-RNA and its genotypes among patients of hemophilia, at hemophilia treatment centre Pakistan institute of medical sciences, Islamabad. Int J 2009;7:84-7.

Waheed Y, Shafi T, Safi SZ, Qadri I. Hepatitis C virus in Pakistan: A systematic review of prevalence, genotypes and risk factors. World J Gastroenterol 2009;15:5647-53.

Mohamoud YA, Riome S, Abu-Raddad LJ. Epidemiology of hepatitis C virus in the Arabian Gulf countries: Systematic review and meta-analysis of prevalence. Int J Infect Dis 2016;46:116-25.

Rikabi A, Bener A, Al-Marri A, Al-Thani S. Hepatitis B and C viral infections in chronic liver disease: A population based study in Qatar. East Mediterr Health J 2009;15:778-84.

Mohamoud YA, Mumtaz GR, Riome S, Miller D, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Egypt: A systematic review and data synthesis. BMC Infect Dis 2013;13:288.

Biswas A, Sarkar K, Firdaus R, Saha K, Gupta D, Ghosh M, et al. Prevalence of anti-HCV, HBsAg, HIV among multi-transfused thalassemic individuals and their socio-economic background in Eastern India. Asian J Pharm Clin Res 2016;9:314-8.

Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333 42.

Tarky MA, Akram W, Al-Naaimi S, Ali O. Epidemiology of viral hepatitis B and C in Iraq: A national survey 2005-2006. Zanco J Med Sci 2013;17:370-80.

World Health Organization. Hepatitis C. WHO Fact Sheets. Geneva; 2000. Available from: https://www.who.int/csr/resources/publications/ hepatitis/en/. [Last accessed on 2016 Aug 20].

Fadlalla FA, Mohamoud YA, Mumtaz GR, Abu-Raddad LJ. The epidemiology of hepatitis C virus in the Maghreb region: Systematic review and meta-analyses. PLoS One 2015;10:e0121873.

Ataallah TM, Hanan KA, Maysoun KS, Sadoon AA. Prevalence of hepatitis B and C among blood donors attending the national blood transfusion center in Baghdad, Iraq from 2006-2009. Saudi Med J 2011;32:1046-50.

Tashkandy MA, Khodari YA, Ibrahim AM, Dhafar KO, Gazzaz ZJ, Azab BA, et al. Evaluation of the available anti-HCV antibody detection tests and RT-PCR assay in the diagnosis of hepatitis C virus infection. Saudi J Kidney Dis Transpl 2007;18:523-31.

Quiroga JA, Llorente S, Castillo I, Rodríguez-Iñigo E, Pardo M, Carreño V, et al. Cellular immune responses associated with occult hepatitis C virus infection of the liver. J Virol 2006;80:10972-9.

Lee YJ, Chang CT, Wu MS. Acute hepatitis C infection without anti- HCV antibody in chronic hemodialysis patient. Chang Gung Med J 2006;29 Suppl 4:35-8.

Gupta E, Bajpai M, Choudhary A. Hepatitis C virus: Screening, diagnosis, and interpretation of laboratory assays. Asian J Transfus Sci 2014;8:19-25.

Dhawan VK. Hepatitis C Clinical Presentation. Medscape; 2018. Available from: https://www.emedicine.medscape.com/article/177792- clinical. [Last accessed on 2016 Sep 10].

Mojtabavi NM, Derakhshan F, Hourfar H, Derakhshan R, Rajab FM. Analysis of the related factors in hepatitis C virus infection among hemophilic patients in Isfahan, Iran. Hepat Mon 2007;7:59-62.

Published

07-01-2019

How to Cite

Abdul Razak, M. K. “THE PREVALENCE OF HEPATITIS C VIRUS INFECTION AND POTENTIAL RISK FACTORS AMONG MULTIPLY TRANSFUSED PATIENTS”. Asian Journal of Pharmaceutical and Clinical Research, vol. 12, no. 1, Jan. 2019, pp. 473-7, doi:10.22159/ajpcr.2019.v12i1.29515.

Issue

Section

Original Article(s)